Resources » WFH Gene Therapy Registry – Basics of hemophilia, gene therapy, and long-term data collection
LINKS
DETAILS

Year: 2022

Language: English

This resource is also available in: French Spanish

This resource is also available in: French, Spanish, German, Italian

Author(s): World Federation of Hemophilia

Format: Document

WFH Gene Therapy Registry – Basics of hemophilia, gene therapy, and long-term data collection

ADDITIONAL INFORMATION

This document is an introductory guide to the World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR). It answers basic questions about the registry, its purpose, and what participants can expect. The guide is designed to help those who receive gene therapy for hemophilia and their care teams to decide if they should participate in the registry.

Please reach out to WFH with questions regarding participation in the registry at [email protected].

The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

RELATED RESOURCES